Amplia Therapeutics is partnering with pharmaceutical company Eli Lilly to run a clinical trial testing a combination of their respective therapies for non-small-cell lung cancer (NSCLC), according to multiple Australian outlets. The reporting states that the companies’ collaboration focuses on evaluating whether combining Amplia’s treatment approach with Lilly’s drug therapy can improve outcomes for patients with NSCLC.
All sources describe the move as a drug-development partnership centered on a trial rather than an approved product or a finalized regulatory decision. The articles do not provide further details in the provided text on trial phase, study size, specific drugs involved, or trial locations.
Overall, the coverage is consistent in identifying the same two companies—Amplia Therapeutics and Eli Lilly—and the same cancer indication—non-small-cell lung cancer—framed around testing a combined therapy in a clinical study.
